Evidence map›Paper›PMID 24322510›Full record

Trial reportEuropean radiology2014

Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT.

Katrijn Michielsen, Ignace Vergote, Katya Op de Beeck, Frederic Amant, Karin Leunen, Philippe Moerman, Christophe Deroose, Geert Souverijns, Steven Dymarkowski, Frederik De Keyzer and 1 more

2 registry-linked trialsAbstract readClinical TrialComparative Study
PubMed Publisher
In one paragraph

Trial report in European radiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 91 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 8 pooled it
21.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02334371 nacompletednot on this mapstarted 2015, after this paper: background citation

MR-PET for Staging and Assessment of Operability in Ovarian Cancer - a Feasibility Study

TypeinterventionalSponsorMaastricht University Medical CenterRan2015 to 2016Enrolled10ConditionsOvarian NeoplasmsArmsMR-PET
NCT06084195 narecruitingnot on this mapstarted 2023, after this paper: background citation

Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging

TypeinterventionalSponsorInstitut du Cancer de Montpellier - Val d'AurelleRan2023 to 2029Enrolled120ConditionsHigh Grade Serous Ovarian CancerArmsBlood sample and tissue sample
3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 8 syntheses or guidelines pooled it, 233 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Guideline
  8. Pooled it
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Katrijn MichielsenDepartment of Radiology, Medical Imaging Research Centre, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Ignace Vergote
Katya Op de Beeck
Frederic Amant
Karin Leunen
Philippe Moerman
Christophe Deroose
Geert Souverijns
Steven Dymarkowski
Frederik De Keyzer
Vincent Vandecaveye
KU Leuven · BEJessa Hospital · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate whole-body MRI with diffusion-weighted sequence (WB-DWI/MRI) for staging and assessing operability compared with CT and FDG-PET/CT in patients with suspected ovarian cancer.

methodsThirty-two patients underwent 3-T WB-DWI/MRI, (18) F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and CT before diagnostic open laparoscopy (DOL). Imaging findings for tumour characterisation, peritoneal and retroperitoneal staging were correlated with histopathology after DOL and/or open surgery. For distant metastases, FDG-PET/CT or image-guided biopsies were the reference standards. For tumour characterisation and peritoneal staging, WB-DWI/MRI was compared with CT and FDG-PET/CT. Interobserver agreement for WB-DWI/MRI was determined.

resultsWB-DWI/MRI showed 94 % accuracy for primary tumour characterisation compared with 88 % for CT and 94 % for FDG-PET/CT. WB-DWI/MRI showed higher accuracy of 91 % for peritoneal staging compared with CT (75 %) and FDG-PET/CT (71 %). WB-DWI/MRI and FDG-PET/CT showed higher accuracy of 87 % for detecting retroperitoneal lymphadenopathies compared with CT (71 %). WB-DWI/MRI showed excellent correlation with FDG-PET/CT (κ = 1.00) for detecting distant metastases compared with CT (κ = 0.34). Interobserver agreement was moderate to almost perfect (κ = 0.58-0.91).

conclusionsWB-DWI/MRI shows high accuracy for characterising primary tumours, peritoneal and distant staging compared with CT and FDG-PET/CT and may be valuable for assessing operability in ovarian cancer patients. KEY POINTS: • Whole-body MRI with diffusion weighting (WB-DWI/MRI) helps to assess the operability of suspected ovarian cancer. • Interobserver agreement is good for primary tumour characterisation, peritoneal and distant staging. • WB-DWI/MRI improves mesenteric/serosal metastatic spread assessment compared with CT and FDG-PET/CT. • Retroperitoneal/cervical-thoracic nodal staging using qualitative DWI criteria was reasonably accurate. • WB-DWI/MRI and FDG-PET/CT showed the highest diagnostic impact for detecting thoracic metastases.

Indexed as

Whole Body ImagingAdultAgedAged, 80 and overCarcinomaDiffusionDiffusion Magnetic Resonance ImagingFeasibility StudiesFemaleFluorodeoxyglucose F18HumansImage-Guided BiopsyLymph NodesMiddle AgedNeoplasm StagingOvarian NeoplasmsFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

PMID24322510
OpenAlexW1970515848

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.